



19 May 2020

ASX ANNOUNCEMENT

Anti-calcification comparison study

Admedus Limited (ASX:AHZ) (**Admedus** or the **Company**) announces the commencement of a preclinical study that will compare anti-calcification properties of its proprietary ADAPT[®] treated tissue with other bovine and porcine tissues that are used currently in commercially available SAVR and TAVR valves. Calcification plays a significant role in the failure of bioprosthetic and other tissue heart valve substitutes.

The study will be conducted in Minneapolis, USA at a world-renowned preclinical facility. The aim of this study is to evaluate anti-calcification properties in the established subcutaneous rat model.

Forty-eight (48) rats will be implanted. Harvested implants will be processed for histological and calcium/phosphorus analysis initially at the end of four months.

“Collecting and building data proving superiority of ADAPT[®] tissue against current treatments in the TAVR market is an important step towards ultimate commercialization. Such data builds a positive benefit-risk profile for new ADAPT[®] treated tissue products, for which regulatory initiatives may reveal a fast path to market,” the Company’s Chief Executive Officer, Mr Wayne Paterson, said.

ENDS

About Admedus Limited (ASX: AHZ)

Admedus Ltd is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Its focus is on developing next generation technologies with world class partners.

Admedus Limited


Registered Office:

Suite 302, Level 3 Toowong Tower, 9 Sherwood Road, Toowong QLD 4066

Customer Service:

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299

E: info@admedus.com W: admedus.com





Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer

For more information:

Ms Kyahn Williamson

WE Communications

E: WE-AUAdmedus@we-worldwide.com

P: +61 401 018 828

www.admedus.com

Twitter: @Admedus

Facebook: www.facebook.com/Admedus

